Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.63 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.50 |
| ▸ | AXL | P30530 | 1/20 | 0.50 |
| ▸ | NEK2 | P51955 | 1/20 | 0.50 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 2/20 | 0.47 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 2/20 | 0.46 |
| ▸ | JAK3 | P52333 | 2/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24072016 | 0.91 | EGFR (0.56) | EGFRFGFR1BRD4JAK2JAK3 | |
| SCHEMBL26379047 | 0.91 | EGFR (0.51) | EGFRFGFR1AXLNEK2ALK | |
| SCHEMBL26379016 | 0.90 | EGFR (0.50) | EGFRAXLNEK2IGF1RJAK2 | |
| SCHEMBL26379032 | 0.89 | AXL (0.51) | EGFRAXLJAK2JAK3 | |
| SCHEMBL26378975 | 0.88 | ALK (0.58) | EGFRIGF1RALKJAK3 | |
| SCHEMBL26395616 | 0.88 | EGFR (0.66) | EGFRFGFR1AXLNEK2TNK2 | |
| SCHEMBL26379123 | 0.87 | EGFR (0.52) | EGFRFGFR1AXLIGF1RALK | |
| SCHEMBL26378979 | 0.86 | EGFR (0.49) | EGFRTNK2IGF1RALKJAK3 | |
| SCHEMBL26379058 | 0.86 | EGFR (0.49) | EGFRALKJAK3 | |
| SCHEMBL24072109 | 0.85 | CDK1 (0.48) | EGFRIGF1RALKPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310428-A1 | EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF | EGFR, ERBB2, ERBB4 | EGFR 1/4885FGFR1 59/4885AXL 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.